Conradi, Lena-Christin

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Azizian, A."],["dc.contributor.author","Bernhardt, M."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Koenig, A."],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:20:53Z"],["dc.date.available","2018-11-07T10:20:53Z"],["dc.date.issued","2016"],["dc.format.extent","75"],["dc.identifier.isi","000371353700239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41971"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Heterogeneity of KRAS Mutation Status in Rectal Cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Ruehlmann, Felix"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.date.accessioned","2018-11-07T09:34:12Z"],["dc.date.available","2018-11-07T09:34:12Z"],["dc.date.issued","2014"],["dc.identifier.isi","000343816900255"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32127"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.title","SRC expression in locally advanced rectal cancer-before and after neoadjuvant chemoradiotherapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","187"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Homayonfaur, K."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Yildirim, Muejdat"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T08:55:28Z"],["dc.date.available","2018-11-07T08:55:28Z"],["dc.date.issued","2011"],["dc.format.extent","46"],["dc.identifier.isi","000291236200125"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22909"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","17th Annual Meeting of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Wiesbaden, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","A lack of down-regulation of survivin after neoadjuvant Chemoradiotherapy for Rectal cancer with distant metastasis and Reduced survival rate linked"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","187"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Mergler, Caroline Patricia Nadine"],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.date.accessioned","2018-11-07T08:55:29Z"],["dc.date.available","2018-11-07T08:55:29Z"],["dc.date.issued","2011"],["dc.format.extent","49"],["dc.identifier.isi","000291236200133"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22914"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.eventlocation","Wiesbaden, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","TGFB1 Pro25 allele as a risk marker for higher-grade acute Organ toxicity (CTC >= Grad2) during neoadjuvant Chemoradiotherapy in patients with locally advanced Rectal cancer (UICC Stage II/III)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","190"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Lorenzen, Stephan"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Quack, H."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Helms, C."],["dc.contributor.author","Frank, M. A."],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.date.accessioned","2018-11-07T09:38:37Z"],["dc.date.available","2018-11-07T09:38:37Z"],["dc.date.issued","2014"],["dc.format.extent","90"],["dc.identifier.isi","000337052500218"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33101"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","20th Annual Congress of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Dusseldorf, GERMANY"],["dc.relation.issn","1439-099X"],["dc.relation.issn","0179-7158"],["dc.title","Cytokinesis-block micronucleus cytome assay for in vivo and in vitro lymphocyte radiosensitivity in patients undergoing radiochemotherapy for locally advanced rectal cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","435"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","435"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H. A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:19Z"],["dc.date.available","2022-06-08T07:57:19Z"],["dc.date.issued","2011"],["dc.description.abstract","435 Background: Fluorouracil (5FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5FU thymidylate synthase (TS) is a promising biomarker in rectal cancer. We assessed TS in 208 patients with regard to its predictive/prognostic capacity for disease free DFS and overall cancer specific survival (CSS). Methods: 167 patients cUICC stages II (28%) and III (72%) received preoperative 5FU based RCT followed by total mesorectal excision (TME) A comparison group n = 41 received postoperative RCT after primary TME. All patients were treated after standardized protocols within phase-II/-III trials of the German Rectal Cancer Study Group. TS levels from pretreatment biopsies and corresponding resection specimens were assessed by immunohistochemical staining for their impact on DFS and CSS. Additionally, a TS gene polymorphism (28 bp repeat) was analysed in respect to intracellular protein expression levels and prognostic significance. Results: Patients with low TS expression in pre-treatment biopsies showed a correlation with impaired CSS (p = 0.015). After neoadjuvant RCT there was evidence of lymph node metastases ypUICC stage III in 32.6%. Complete histopathologically confirmed tumor regression TRG 4 was achieved in 16 patients (9.5%). During follow-up (median 57 months) patients with low intratumoral TS expression and positive nodal status were at high risk for local and/or distant metastatic recurrence (p = 0.040). Analysis of the 28bp repeat revealed a correlation of 3/ 3 genotype with high TS expression in pretherapeutical biopsies (p = 0.05). Conclusions: TS represents a prognostic biomarker in locally advanced rectal cancer indicating an unfavourable outcome for patients with low TS expression and might help to adapt adjuvant therapy regimens by stratifying patients according to their risk for cancer recurrence. No significant financial relationships to disclose."],["dc.identifier.doi","10.1200/jco.2011.29.4_suppl.435"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110056"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma."],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","219"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Dröge, Leif H."],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Lorenzen, Stephan"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Quack, Henriette"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Helms, Christian"],["dc.contributor.author","Frank, Miriam A."],["dc.contributor.author","Schirmer, Markus A."],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Wolff, Hendrik A."],["dc.date.accessioned","2021-04-14T08:28:08Z"],["dc.date.accessioned","2022-08-18T12:34:40Z"],["dc.date.available","2021-04-14T08:28:08Z"],["dc.date.available","2022-08-18T12:34:40Z"],["dc.date.issued","2021-03-04"],["dc.date.updated","2022-07-29T12:07:13Z"],["dc.description.abstract","Abstract\r\n \r\n Background\r\n The question whether lymphocyte radiosensitivity is representative of patients’ response to radiotherapy (RT) remains unsolved. We analyzed lymphocyte cytogenetic damage in patients who were homogeneously treated with preoperative radiochemotherapy (RCT) for rectal cancer within clinical trials. We tested for interindividual variation and consistent radiosensitivity after in-vivo and in-vitro irradiation, analyzed the effect of patients’ and RCT characteristics on cytogenetic damage, and tested for correlations with patients’ outcome in terms of tumor response, survival and treatment-related toxicity.\r\n \r\n \r\n Methods\r\n The cytokinesis-block micronucleus cytome (CBMNcyt) assay was performed on the peripheral blood lymphocytes (PBLCs) of 134 patients obtained before, during, at the end of RCT, and during the 2-year follow-up. A subset of PBLCs obtained before RCT was irradiated in-vitro with 3 Gy. RCT included 50.4 Gy of pelvic RT with 5-fluorouracil (5-FU) alone (n = 78) or 5-FU plus oxaliplatin (n = 56). The analyzed variables included patients’ age, gender, RT characteristics (planning target volume size [PTV size], RT technique), and chemotherapy characteristics (5-FU plasma levels, addition of oxaliplatin). Outcome was analyzed as tumor regression, patient survival, and acute and late toxicity.\r\n \r\n \r\n Results\r\n Cytogenetic damage increased significantly with the radiation dose and varied substantially between individuals. Women were more sensitive than men; no significant age-dependent differences were observed. There was a significant correlation between the cytogenetic damage after in-vitro irradiation and in-vivo RCT. We found a significant effect of the PTV size on the yields of cytogenetic damage after RCT, while the RT technique had no effect. Neither the addition of oxaliplatin nor the 5-FU levels influenced cytogenetic damage. We found no correlation between patient outcome and the cytogenetic damage.\r\n \r\n \r\n Conclusions\r\n We found consistent cytogenetic damage in lymphocytes after in-vivo RCT and in-vitro irradiation. Gender was confirmed as a well-known, and the PTV size was identified as a less well-known influencing variable on lymphocyte cytogenetic damage after partial-body irradiation. A consistent level of cytogenetic damage after in-vivo and in-vitro irradiation may indicate the importance of genetic factors for individual radiosensitivity. However, we found no evidence that in-vivo or in-vitro irradiation-induced cytogenetic damage is an adequate biomarker for the response to RCT in rectal cancer patients."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.citation","BMC Cancer. 2021 Mar 04;21(1):219"],["dc.identifier.doi","10.1186/s12885-021-07914-5"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17741"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82514"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112932"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","BioMed Central"],["dc.relation.eissn","1471-2407"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject","Rectal cancer"],["dc.subject","Radiochemotherapy"],["dc.subject","Cytogenetic damage"],["dc.subject","Micronucleus test"],["dc.subject","Toxicity"],["dc.subject","Survival"],["dc.title","Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","48"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Radiotherapy and Oncology"],["dc.bibliographiccitation.lastpage","54"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Merkel, Susanne"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Raab, Hans-Rudolf"],["dc.contributor.author","Tschmelitsch, Joerg"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Sauer, Rolf"],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:22:42Z"],["dc.date.available","2018-11-07T09:22:42Z"],["dc.date.issued","2013"],["dc.description.abstract","Introduction: The CAO/ARO/AIO-94 phase-III-trial demonstrated a significant improvement of preoperative chemoradiotherapy (CRT) versus postoperative CRT on local control for UICC stage II/III rectal cancer patients, but no effect on long-term survival. In this add-on evaluation, we investigated the association of gender and age with acute toxicity and outcome. Patients and methods: According to actual treatment analyses, 654 of 799 patients had received pre-(n = 406) or postoperative CRT (n = 248); in 145 patients postoperative CRT was not applied. Gender, age and clinicopathological parameters were correlated with CRT-associated acute toxicity and survival. Results: The 10-year survival was higher in women than in men, with 72.4% versus 65.6% for time to recurrence (p = 0.088) and 62.7% versus 58.4% for overall-survival (OS) (p = 0.066), as expected. For patients receiving CRT, women showed higher hematologic (p < 0.001) and acute organ toxicity (p < 0.001) in the entire cohort as well as in subgroup analyses according to pre- (p = 0.016) and postoperative CRT (p < 0.001). Lowest OS was seen in patients without acute toxicity (p = 0.0271). Multivariate analyses for OS showed that acute organ toxicity (p = 0.034) was beneficial while age (p < 0.001) was associated with worse OS. Discussion: Female gender is significantly associated with CRT-induced acute toxicity in rectal cancer. Acute toxicity during CRT may be associated with improved long-term outcome. (C) 2013 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.radonc.2013.05.009"],["dc.identifier.isi","000324155900007"],["dc.identifier.pmid","23768685"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11335"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29411"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","0167-8140"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: Long-term results of the German CAO/ARO/AIO-94 phase III trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Quack, H."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Binder, L."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Lorenzen, Stephan"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:19:02Z"],["dc.date.available","2018-11-07T09:19:02Z"],["dc.date.issued","2013"],["dc.format.extent","73"],["dc.identifier.isi","000326360900167"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28546"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","1423-0240"],["dc.relation.issn","0378-584X"],["dc.title","5-FU dose monitoring under neoadjuvant radiochemotherapy and adjuvant chemotherapy for locally advanced rectal cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","621"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","The Oncologist"],["dc.bibliographiccitation.lastpage","631"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:01:50Z"],["dc.date.available","2018-11-07T09:01:50Z"],["dc.date.issued","2011"],["dc.description.abstract","Patients with locally advanced rectal cancer (cUICC stages II/III) are typically treated with preoperative 5-fluorouracil-based (5-FU-based) radiochemotherapy (RCT). However, trials are currently being conducted to improve the complete remission rates and the systemic control by combining 5-FU with oxaliplatin. The primary objective was to identify the subgroups of rectal cancer patients who were at risk for high-grade toxicity. All 196 patients who were included in the present study were treated with 50.4 Gy and chemotherapy that included either 5-FU (n = 115) or 5-FU + oxaliplatin (n + 81). The preoperative RCT was followed by a total mesorectal excision and adjuvant chemotherapy. Acute toxicity was monitored weekly and a toxicity grade >= 3 (Common Toxicity Criteria) for a skin reaction, cystitis, proctitis, or enteritis was defined as high-grade acute organ toxicity. After RCT with 5-FU + oxaliplatin, complete tumor remission was achieved in 13.6% of the patients and in 11.3% after RCT with 5-FU alone. Complete irradiation dosages of 50.4 Gy were given to 99% (5-FU) and 95% (5-FU + oxaliplatin) of the patients. Concomitant chemotherapy was fully administered in 95% of the patients treated with 5-FU compared with the 84% of patients treated with 5-FU + oxaliplatin. A significantly higher proportion of acute organ toxicity was found in the patients who were treated with 5-FU + oxaliplatin compared with those who were treated with 5-FU. Additionally, women with a low body mass index were at the highest risk for acute organ toxicity. These results suggest that there are basic clinical parameters, such as gender and body mass index, that may be potential markers for generating individual risk profiles of RCT-induced toxicity. The Oncologist 2011;16:621-631"],["dc.identifier.doi","10.1634/theoncologist.2010-0414"],["dc.identifier.isi","000290661900012"],["dc.identifier.pmid","21558132"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24528"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Alphamed Press"],["dc.relation.issn","1083-7159"],["dc.title","Gender-Specific Acute Organ Toxicity during Intensified Preoperative Radiochemotherapy for Rectal Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]